Close Menu

NEW YORK – Oncocyte said Thursday that it has entered a distribution agreement with CORE Diagnostics to expand the commercial availability of its DetermaRx test to India, the Middle East, and Africa.

DetermaRx is Oncocyte’s first commercially launched assay and was initially called the Razor Genomic test when Oncocyte acquired Razor and it's IP last year.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.